9th Mar 2015 14:05
Tissue Regenix Group plc
("Tissue Regenix" or "the Company")
Notice of Preliminary Results
YORK, 9th March 2015 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix"), the regenerative medical devices company, announces that it will publish its unaudited preliminary results for the year ended 31 January 2015, on Monday 11th May 2015.
For Further Information
Tissue Regenix Group Plc: Antony Odell Ian Jefferson
| +44 19 0443 5176 |
Jefferies International Ltd: Simon Hardy Harry Nicholas
| +44 20 7029 8000 |
Tulchan Communications: Tom Buchanan Victoria Huxster
| +44 207 353 4200 |
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.
Related Shares:
Tissue Regenix Group